Vanguard Global Advisers’s Immunic IMUX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$57.3K Buy
6,160
+2,974
+93% +$40.9K ﹤0.01% 3025
2026
Q2
$49K Sell
3,186
-1
-0% -$12 ﹤0.01% 3075
2026
Q1
$35.4K Buy
+3,187
New +$28.5K ﹤0.01% 3151

Other funds holding IMUX

Vanguard Global Advisers's IMUX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Immunic (IMUX) stake by 93% in Q3 2026, buying an estimated $40.9K and bringing the position to 6,160 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Vanguard Global Advisers first reported a position in IMUX in Q1 2026 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold IMUX as of Q3 2026.

  • Vanguard Global Advisers held 6,160 shares of Immunic worth $57.3K as of Q3 2026.
  • Vanguard Global Advisers bought 2,974 Immunic shares in Q3 2026, an estimated $40.9K.
  • Immunic made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3025 holding.
  • Vanguard Global Advisers first reported a position in Immunic in Q1 2026 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held Immunic as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.